Senator Hatch’s proposal to limit biopharma IPRs has come at the wrong time
Lame duck session attempt at reform looks likely to fail given recent changes at the PTAB and growing public concern over drugs pricing in the US
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.